Nantes, France – October 12, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that three abstracts have been accepted for poster presentation at the 37th annual meeting of the SITC (Society for Immunotherapy of Cancer) to be held in Boston in person and virtually from November 8 to 12. These posters will present the latest preclinical data from the innovative BiCKI® and Myeloid research platforms, and in particular on the BiCKI®-IL-7 (bifunctional targeting PD-1 and IL-7) and CLEC-1 (new checkpoint) programs immune myeloid). The Company had also been invited to make an oral presentation on its CLEC-1 program at the Macrophage-directed Therapies Summit in Boston in October 2022.